ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0760

The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis

Sema Kaymaz-Tahra1, Cansu Arslantürk Güneysu2, Sinem Nihal Esatoglu3, Güllü Sandal Uzun4, Burak Ince5, Mete Kara6 and Gulen Hatemi3, 1Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey, 2Sakarya Training and Research Hospital, Division of Rheumatology, Sakarya, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 4Hacettepe University, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 5Istanbul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, 6Izmir City Hospital, Division of Rheumatology, Izmir

Meeting: ACR Convergence 2025

Keywords: , ,

Session Information

Date: Sunday, October 26, 2025

Title: (0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: To assess the sustained remission rates of the targeted therapies in 52th week in patients with giant cell arteritis (GCA).

Methods: We performed a systematic literature review in PUBMED and Scopus databases and performed a metanalysis using Revman. A total of 1085 articles were scanned. We included 60 articles for review. Retrospective studies, non-randomised prospective studies were excluded and only randomised-controlled trials (RCT) were involved. In the meta-analysis 10 RCTs were included. Two independent reviewers extracted the data. The primary outcome was sustained remission (SR) rate at the 52th week of the treatment. The SR rates for similar glucocorticoid tapering arms in the targeted therapy and placebo groups were compared.

Results: A total of 869 patients were included in the involved studies. All the studies compared the outcomes with placebo. No head-to-head comparison was performed. SR rates were significantly higher compared to placebo in the patients who received tocilizumab (tocilizumab IV RR(CI 1.90 (1.01-3.56), tocilizumab SC 1.45 (1-06-1.99)), mavrilumab (RR (CI) 1.67(1.12-2.47)), secukinumab (RR(CI): 7.41 (1.89-29.02)) and upadacitinib 15 mg (RR (CI) 1.58 (1.14-2.17). On the contrary, the sustained remission rate was found to be similar to placebo with the study drug in studies conducted with sarilumab and sirukumab. Safety outcomes of targeted drugs were similar with placebo in all of the involved studies.

Conclusion: Tocilizumab, mavrilumab, secukinumab and upadacitinib appear to increase the rate of 52-week sustained remission rate. Sarilumab and sirukumab has not shown significant efficacy.

Supporting image 1Figure 1. Meta-analysis of the effect of the targeted therapies on the sustained remission at the 52th week of treatment

Disclosures: S. Kaymaz-Tahra: None; C. Arslantürk Güneysu: None; S. Esatoglu: None; G. Sandal Uzun: None; B. Ince: None; M. Kara: None; G. Hatemi: AbbVie/Abbott, 6, Amgen, 6, Boehringer-Ingelheim, 2, Novartis, 6, Pfizer, 6, UCB, 6.

To cite this abstract in AMA style:

Kaymaz-Tahra S, Arslantürk Güneysu C, Esatoglu S, Sandal Uzun G, Ince B, Kara M, Hatemi G. The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-efficacy-of-targeted-therapies-in-giant-cell-arteritis-a-systematic-review-and-meta-analysis/. Accessed .

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-efficacy-of-targeted-therapies-in-giant-cell-arteritis-a-systematic-review-and-meta-analysis/